These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30660493)

  • 41. Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy.
    Deniffel D; Perlis N; Ghai S; Girgis S; Healy GM; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA
    Eur Radiol; 2022 Nov; 32(11):7544-7554. PubMed ID: 35507051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
    Schoots IG; Roobol MJ; Nieboer D; Bangma CH; Steyerberg EW; Hunink MG
    Eur Urol; 2015 Sep; 68(3):438-50. PubMed ID: 25480312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE).
    Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Machado A; Levental M; Ghai S; Chang SD; Patel C; Kassam Z; Loblaw A; Kebabdjian M; Pond G; Haider MA
    Eur Urol Oncol; 2024 Jun; 7(3):456-461. PubMed ID: 37838556
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
    Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study.
    Porreca A; Del Giudice F; Giampaoli M; D'Agostino D; Romagnoli D; Corsi P; Del Rosso A; Maggi M; Chung BI; Ferro M; de Cobelli O; Lucarelli G; Schiavina R; De Berardinis E; Sciarra A; Busetto GM
    Medicine (Baltimore); 2020 Sep; 99(37):e22059. PubMed ID: 32925739
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of anterior prostate cancer using a magnetic resonance imaging-transrectal ultrasound fusion biopsy in cases with initial biopsy and history of systematic biopsies.
    Abe M; Takata R; Ikarashi D; Sekiguchi K; Tamura D; Maekawa S; Kato R; Kanehira M; Ujiie T; Obara W
    Prostate Int; 2023 Dec; 11(4):212-217. PubMed ID: 38196555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: A comparative real-life study.
    Pham THN; Schulze-Hagen MF; Rahnama'i MS
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1962. PubMed ID: 38217298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis.
    Sidana A; Watson MJ; George AK; Rastinehad AR; Vourganti S; Rais-Bahrami S; Muthigi A; Maruf M; Gordetsky JB; Nix JW; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
    Urol Oncol; 2018 Jul; 36(7):341.e1-341.e7. PubMed ID: 29753548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
    Pellegrino F; Stabile A; Mazzone E; Sorce G; Barletta F; De Angelis M; Brembilla G; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
    Prostate; 2022 Sep; 82(12):1170-1175. PubMed ID: 35538401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.
    Maxeiner A; Kittner B; Blobel C; Wiemer L; Hofbauer SL; Fischer T; Asbach P; Haas M; Penzkofer T; Fuller F; Miller K; Cash H
    BJU Int; 2018 Aug; 122(2):211-218. PubMed ID: 29569320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
    De Luca S; Passera R; Cattaneo G; Manfredi M; Mele F; Fiori C; Bollito E; Cirillo S; Porpiglia F
    BJU Int; 2016 Nov; 118(5):723-730. PubMed ID: 27112799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Power Doppler Sonography (PDS) and Modified TRUS Systematic Biopsies - Can this Combination Adequately Replace Multiparametric Prostate Magnetic Resonance Imaging (mp-MRI) in Candidates for Re Biopsies Who cannot Undergo mp-MRI.
    Kravchick S; Cherniavsky E; Peled R; Cytron S; Verhovsky G
    Pathol Oncol Res; 2020 Oct; 26(4):2357-2361. PubMed ID: 32504311
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
    Sorce G; Stabile A; Pellegrino F; Mazzone E; Mattei A; Afferi L; Serni S; Minervini A; Roumiguiè M; Malavaud B; Valerio M; Rakauskas A; Marra G; Gontero P; Porpiglia F; Guo H; Zhuang J; Gandaglia G; Montorsi F; Briganti A
    World J Urol; 2024 Apr; 42(1):248. PubMed ID: 38647689
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
    Kato D; Ozawa K; Takeuchi S; Kawase M; Kawase K; Nakai C; Takai M; Iinuma K; Nakane K; Kato H; Matsuo M; Suzui N; Miyazaki T; Koie T
    Curr Oncol; 2021 Mar; 28(2):1294-1301. PubMed ID: 33809967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of TRUS and combined MRI-targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology.
    Aslan G; Çelik S; Sözen S; Akdoğan B; İzol V; Yücel Bilen C; Sahin B; Türkeri L;
    Int J Clin Pract; 2021 Mar; 75(3):e13797. PubMed ID: 33113261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study.
    Washino S; Kobayashi S; Okochi T; Kameda T; Konoshi T; Miyagawa T; Takayama T; Morita T
    BMC Urol; 2018 May; 18(1):51. PubMed ID: 29843694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.